A 2025 observational analysis by MD Anderson Cancer Center and the University of Florida of nearly 1,000 advanced cancer patients receiving checkpoint inhibitor therapy found that patients who received a Pfizer or Moderna mRNA COVID-19 vaccine within 100 days of starting treatment had substantially longer survival; specifically, vaccinated lung cancer patients were nearly twice as likely to be alive three years after beginning cancer treatment compared with unvaccinated patients.
October 22, 2025
high
study_finding
Retrospective observational analysis of patient records comparing outcomes for those who did and did not receive mRNA COVID-19 vaccines around start of checkpoint inhibitor therapy.